ResMed RMD
ResMed is a medical device company that designs and sells solutions for sleep apnea and other respiratory conditions, including masks and ventilators. ResMed shows solid financial health (DN/EBITDA of -0.31, operating margin of 30.86%) and high quality (ROE 24.27%), with revenue growth of 8.60% that could accelerate thanks to sleep therapy demand linked to GLP-1 patients, although valuation (P/E 21.28) is not particularly attractive and momentum is weak (-10.14%).
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
ResMed is a medical device company that designs and sells solutions for sleep apnea and other respiratory conditions, including masks and ventilators. ResMed shows solid financial health (DN/EBITDA of -0.31, operating margin of 30.86%) and high quality (ROE 24.27%), with revenue growth of 8.60% that could accelerate thanks to sleep therapy demand linked to GLP-1 patients, although valuation (P/E 21.28) is not particularly attractive and momentum is weak (-10.14%).
Score by category
| Category | Score |
|---|---|
| Financial health | 8.7 |
| Quality / Moat | 8.0 |
| Valuation | 5.3 |
| Growth | 6.1 |
| Dividend | 5.1 |
| Momentum | 3.0 |
| Risk & Context | 7.2 |
OVERALL SCORE: 6.6/10
Context and risks
ResMed has no direct exposure to rates, oil, or geopolitics; its medical device business is defensive. The only relevant factor is the rise in 10-year yields (5.17%), which marginally affects the valuation of future cash flows, but its P/E of 21.28 is not of extreme duration, so the impact is limited.
News considered in the analysis
- ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand — La guía de crecimiento de BPA del 12-14% y la demanda impulsada por pacientes GLP-1 (que aumentan la necesidad de terapia del sueño) es un catalizador material para el crecimiento futuro.
- ResMed Inc. (RMD)’s Sleep Apnea Leadership Supports Growth Despite Rising Competitive Pressures — Reafirma el liderazgo en apnea del sueño, pero reconoce presiones competitivas crecientes; el efecto neto es moderadamente positivo.
- Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like. — Upgrade de analista con visión positiva; ya reflejado parcialmente en el precio, pero añade soporte a la tesis de crecimiento.
- This Analyst Just Upgraded ResMed Stock. Here's Why. — Segundo upgrade de analista; refuerza la confianza en el crecimiento, aunque es información redundante con la anterior.
- Is Margin Pressure From Rising Costs Altering The Investment Case For ResMed (RMD)? — Plantea presión de márgenes por costes crecientes; aunque el margen operativo actual es alto (30.86%), es un riesgo a vigilar.
Verdict: Hold; quality and expected growth justify the position, but valuation and momentum limit upside potential in the short term.
Main risk: The main risk is competitive pressure in the sleep apnea device market, which could erode the 30.86% operating margin if costs keep rising or new competitors gain share.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →